Drug intelligence / Profile preview

LNH-450

Development stage: Preclinical
Lead developer: Lennham Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

LNH-450 is a deuterated small molecule analog of testosterone currently in preclinical development by Lennham Pharmaceuticals. By utilizing deuterium substitution, the compound is designed to enhance metabolic stability and improve the pharmacokinetic profile of testosterone, specifically targeting the challenges of oral delivery such as high first-pass metabolism. LNH-450 acts as an agonist of the androgen receptor and is being investigated for the treatment of male hypogonadism, female sexual dysfunction, and androgen receptor-positive breast cancer. The goal of this deuterated formulation is to provide a safer and more convenient oral alternative to existing testosterone replacement therapies and hormonal treatments.

Other names: deuterated testosterone

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on LNH-450.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNH-450.

Explore the full profile